Improvement and Safety of Nutrilite Protein MetX Pro on Weight Management in Overweight Individuals With Dyslipidemia

NCT07094022 | Completed

• 1 other identifier: 23-RD-08-AY-001
• Study Type: interventional
• Target: 66
• Locations: 1 country
• Sites: 2

Brief Summary

The goal of this randomized, double-blind, placebo-controlled, single center study is to evaluate the impact of Nutrilite Protein MetX Pro (the study product, a high-protein compound beverages supplemented with multiple plant proteins and apple extracts) on lipid profiles in the blood test in overweight individuals with dyslipidemia. The main question it aims to answer is: \- Does the intake of the study product improve the blood lipid profiles (TC,TG, LDL-C ) in terms of of overweight individuals with dyslipidemia? Researchers will compare the product group to a placebo group to see whether the blood lipid profile is significantly better improved for participants in the product group. Participants will:

• take randomly assigned products 16g/each time, twice a day for 4 weeks
• make four times site visits, once a week. Blood samples are collected for each visit, and Feces are collected for the first and last site visit.

Conditions

Dyslipidemia; Obesity &Amp; Overweight

Keywords

High-protein Compound Beverages; Nutrilite Protein MetX pro

Outcome Measures

Primary Outcomes (3)

• Lipid profile index-TC

  TC (Total Cholesterol) concentration level in the blood sample test: normal range 3-5.2 mmol/L; higher than 5.2 mmol/L is abnormal.

  baseline day 0, day 28

• Lipid profile index-TG

  TG (Triglyceride) concentration level in the blood sample test : normal range 0\~1.7 mmol/L, higher than 1.7mmol/L is abnormal

  baseline day 0, day 28

• Lipid profile index-LDL-C

  LDL-C(Low-Density Lipoprotein Cholesterol) concentration level in the blood sample test: normal range 0-3.1mmol/L, higher than 3.1 mmol/L is abnomal;

  baseline day 0, day 28

Secondary Outcomes (1)

• Number of AE and SAE

  baseline day 0, through day 28

Study Arms (2)

Nutrilite Protein MetX Pro

ACTIVE COMPARATOR

Nutrilite protein MetX pro, 460g per pack. Ingredients: Mung bean protein, chickpea protein, isomaltulose, rice (glutinous rice) protein, green apple concentrated juice powder, inulin, xanthan gum, guar gum, silicon dioxide, food flavoring.

Dietary Supplement: Nutrilite Protein MetX Pro

Placebo Product

PLACEBO COMPARATOR

Placebo product , 460g per pack. Ingredient: Maltodextrin.

Dietary Supplement: Placebo Product

Interventions

Nutrilite Protein MetX Pro DIETARY_SUPPLEMENT

A total of 4 cans (460 g/can) of study products (Nutrilite Protein MetX Pro) are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.

Nutrilite Protein MetX Pro

Placebo Product DIETARY_SUPPLEMENT

A total of 4 cans (460 g/can) of placebo products are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.

Placebo Product

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: 18-65 years old
• Overweight or obese participants, 40 with a BMI of 24-28 kg/m², and 40 participants with a BMI greater than 28. The percentage of male participants is ≥40%. And the lipid profile with the following characteristics:
• TC (Total Cholesterol): 5.18-6.21 mmol/L;
• TG(Triglyceride): 1.70-2.25 mmol/L;
• LDL-C(Low-Density Lipoprotein Cholesterol): ≥ 3.4 mmol/L;
• Agree to sign the informed consent form.

You may not qualify if:

• Pregnant or lactating women, those with allergic constitutions, or those allergic to this test sample.
• Patients with severe diseases of the heart, liver, kidneys and hematopoietic system, as well as those with mental illness.
• Those who have taken lipid-lowering drugs or the like in the past two weeks, which has affected their judgment of the results.
• Patients with hyperlipidemia.
• The researcher determined that the participant was not suitable for this trial.

Sponsors & Collaborators

• Amway (China) R&D Center: lead

Study Sites (2)

Raison Biotech Group Shanghai Lab

Shanghai, Shanghai Municipality, China

Location

Jinhua Wenrong Hospital

Jinhua, Zhejiang, China

Location

MeSH Terms

Conditions

Dyslipidemias; Obesity; Overweight

Condition Hierarchy (Ancestors)

Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Dan Cao

  Jinhua Wenrong Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 22, 2025
• First Posted: July 30, 2025
• Study Start: March 16, 2025
• Primary Completion: June 3, 2025
• Study Completion: June 3, 2025
• Last Updated: July 30, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)